|
1) Katoh T, Mitamura H, Matsuda N, et al. Emer-gency treatment with nifekaranto, a novel class III antiarrhythmic agent, for life-threatening refractory ventricular tachyarrythmias. Post-marketing special investigation. Circ J. 2005; 69: 1237-43
|
|
|
|
2) Ohashi J, Yasuda S, Miyazaki S, et al. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride. J Cardiovasc Pharmacol. 2006; 48: 274-9
|
|
|
|
|
|
3) Ando J, Kakishita M, Sakai K, et al. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease. Int Heart J. 2005; 46: 647-56
|
|
|
|
|
|
4) Tahara Y, Kimura K, Kosuge M, et al. Compari-son of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J. 2006; 70: 442-6
|
|
|
|
|
|
5) Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999; 341: 871-8
|
|
|
|
|
|
6) Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002; 346: 884-90
|
|
|
|
|
|
7) 加藤貴雄. 薬物療法の最近の話題: アミオダロン静注薬の位置づけと使い方. 循環器科. 2007; 61: 419- 23
|
|
|
|
|
|
8) 児玉逸雄, 相澤義房, 井上 博, 他. 不整脈薬に関するガイドライン(JCS2004). Circ J. 2004; 68 Suppl IV: 981-1053
|
|
|
|
|
|
9) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2006; 114: 385-484
|
|
|
|
|
|
10) 日本版救急蘇生ガイドライン策定小委員会. わが国の新しい救急蘇生ガイドライン. 東京: 日本救急医療財団; 2006
|
|
|
|
|